The estimated Net Worth of George Demetri is at least $2.63 millió dollars as of 21 June 2022. George Demetri owns over 10 units of Blueprint Medicines Corp stock worth over $503,952 and over the last 8 years he sold BPMC stock worth over $1,680,058. In addition, he makes $450,643 as Independent Director at Blueprint Medicines Corp.
George has made over 10 trades of the Blueprint Medicines Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 10 units of BPMC stock worth $827 on 21 June 2022.
The largest trade he's ever made was selling 6,250 units of Blueprint Medicines Corp stock on 27 February 2018 worth over $551,813. On average, George trades about 780 units every 63 days since 2016. As of 21 June 2022 he still owns at least 5,822 units of Blueprint Medicines Corp stock.
You can see the complete history of George Demetri stock trades at the bottom of the page.
Dr. George D. Demetri M.D. serves as Independent Director of the Company. He has served as a member of our board of directors since December 2014. Since 1989, Dr. Demetri has served on the faculty of the Dana-Farber Cancer Institute, or DFCI, and Harvard Medical School, where he is a Professor of Medicine and serves as a co-Director of the Ludwig Center at Harvard. At DFCI, Dr. Demetri is the Senior Vice President for Experimental Therapeutics, as well as an Associate Director for Clinical Sciences at the NCI-designated Dana-Farber/Harvard Comprehensive Cancer Center Consortium. Dr. Demetri’s research and clinical interests have centered on mechanism-based drug development for solid tumors, with an emphasis on molecularly-defined subsets of sarcomas such as gastrointestinal stromal tumors. Dr. Demetri has contributed to the development of several new drugs for sarcomas and other malignancies, including imatinib, sunitinib, dasatinib, trabectedin, everolimus, pazopanib and regorafenib. He was also a member of the scientific advisory board for Plexxikon Inc. and helped to develop the mutant BRAF inhibitor, vemurafenib. In addition, Dr. Demetri has served as a member of the board of directors and organization and compensation committee of Merrimack Pharmaceuticals, Inc. since December 2017. Dr. Demetri serves as chair of the Science Policy and Government Affairs Committee for the American Association for Cancer Research as well as several other scientific and editorial advisory boards. Dr. Demetri received an A.B. in biochemistry from Harvard College and an M.D. from Stanford University School of Medicine. Demetri’s more than 25 years of experience as an oncologist and his significant leadership experience on various national and international scientific and company advisory boards qualifies him to serve as a member of our board of directors.
As the Independent Director of Blueprint Medicines Corp, the total compensation of George Demetri at Blueprint Medicines Corp is $450,643. There are 18 executives at Blueprint Medicines Corp getting paid more, with Jeffrey Albers having the highest compensation of $9,362,370.
George Demetri is 63, he's been the Independent Director of Blueprint Medicines Corp since 2014. There are 1 older and 27 younger executives at Blueprint Medicines Corp. The oldest executive at Blueprint Medicines Corp is Mark Goldberg, 65, who is the Independent Director.
George's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 10 years, insiders at Blueprint Medicines Corp have traded over $126,865,732 worth of Blueprint Medicines Corp stock and bought 131,110 units worth $2,599,105 . The most active insiders traders include Llc Fmr, Kevin P Starr és Lonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of $1,362,195. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth $1,685,900.
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
Blueprint Medicines Corp executives and other stock owners filed with the SEC include: